Global Human Papillomavirus (HPV) Therapeutics Market to Reach US$2.34 bn by 2020

Global Human Papillomavirus (HPV) Therapeutics
Market to Reach US$2.34 bn by 2020, Driven by
Rising Prevalence of HPV Infections
The prevalence of human papillomavirus (HPV) is rising among individuals in both developed
and developing countries, imparting a massive boost to the global market for HPV therapeutics,
says Transparency Market Research. The business intelligence firm projects that the global HPV
therapeutics market, which approximated US$1.40 bn in 2012, will exhibit a strong CAGR of
7.7% between 2014 and 2020 and stand at US$2.34 bn by 2020. The report that states these
findings also includes a comprehensive study on the global cytomegalovirus therapeutics market.
According to TMR, the global CMV therapeutics market had a valuation of US$870.1 mn in
2012 and will stand at US$922.8 mn by 2020 at a 1.49 % CAGR from 2014 through 2020.
According to the report, researchers have identified over 100 strains of HPV so far. Of these
strains, a few are known to lead to papillomas or warts, which grow to develop into either
malignant or benign cancers. Young adults and adolescents are at the highest risk of contracting
HPV infections, and the highest prevalence of the same is seen among adolescent females. The
CDC estimates that as of 2012, about 20 million Americans were infected by HPV. This has led
to a high demand for therapies to treat both human papillomavirus and cytomegalovirus
infections.
The HPV therapeutics market is composed of the following drug classes: immunomodulators,
anti-neoplastic agents, sinecatechins, and keratolytic agents. Of these, the largest share of the
HPV therapeutics market was held by immunomodulators. The fastest growth will be seen in the

sinecatechins segment. Basis application, the majority of HPV therapeutics will be used to treat
genital warts until 2020, the report finds. This segment will contribute to the highest share of
revenue to the global HPV therapeutics market.
The HPV therapeutics market is expected to be imparted a blow from a relatively dry pipeline of
drugs and the availability of various substitutes in the form of laser therapy and cryotherapy. This
will decrease the attractiveness of the market during the report’s forecast period. From the
regional perspective, the markets of South America and Asia Pacific will be most attractive to
investors as the prevalence of STDs is increasing in these regions.
On the cytomegalovirus infections therapeutics market, the report states that symptomatic CMV
infections mostly prevail in patients infected with HPV or those who have undergone a
transplant. Basis antiviral drugs, the CMV therapeutics market can be segmented into
ganciclovir/valganciclovir (first line drugs), cidofovir, and foscarnet. Of these, ganciclovir and
valganciclovir together contribute over 85% of all revenue to the CMV therapeutics market
globally. CMV, owing to high seroprevalence of approximately 95% in middle- and low-income
countries, threatens to infect a large portion of the population. This is compounded by the fact
that many HIV patients are now showing resistance to ganciclovir and valganciclovir. The CMV
therapeutics market could receive a boost with the slated launch of letermovir (2018) and
brincidofovir (2016).
The companies that dominate the HPV therapeutics market and CMV therapeutics market,
respectively, are Valeant Pharmaceuticals (70% of the market) and Roche AG (85% of the
market).
The Global HPV and CMV therapeutics market is segmented as follows:
HPV Therapeutics Market, by Drug Class
Immunomodulators
Keratolytic Agents
Anti-neoplastic Agents
Sinecatechins
HPV Therapeutics Market, by Application
Genital Warts
Genital Cancer
Epidermodysplasia Verruciformis
Oral Papillomas
Others (Oropharyngeal cancer, laryngeal papillomatosis and others)
CMV Therapeutics Market, by Major Antiviral Drugs
Ganciclovir/Valganciclovir
Foscarnet

Cidofovir
CMV Therapeutics Market, by Applications
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others (Mouth ulcers, pharyngitis)
Global HPV and CMV Therapeutics Market, by Geography
North America
Europe
Asia Pacific
South America
Rest of the World
About Us
Transparency Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight for thousands of decision
makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that
it always reflects the latest trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for business reports.

Contact Us
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website:http://www.transparencymarketresearch.com